It’s a rare feat for a biotech company to win the endorsement of one top Wall Street analyst. To secure votes of confidence from two in quick succession is a surefire way to grab the market’s attention. That is exactly the scenario unfolding at Edgewise Therapeutics (EWTX).
Last month, Piper Sandler analyst Yasmeen Rahimi reiterated the stock as one of her firm’s top picks for the year. This week, JPMorgan’s Tessa Romero followed suit, significantly hiking her price target on the company. The market has taken notice, with shares consistently outpacing the broader market.
While their recommendations arrived separately, the logic driving both analysts points to the same source: meaningful progress within Edgewise’s drug pipeline.
Despite their different approaches, both analysts zero in on the same core asset: EDG-7500, the company’s investigational treatment for hypertrophic cardiomyopathy (HCM).
For JPMorgan’s Romero, renewed enthusiasm for this candidate was the primary catalyst for her updated outlook. In a research note, she described EDG-7500 as the company’s “lead pipeline asset” and argued its therapeutic potential is far greater than the market had previously appreciated.
Piper Sandler’s Rahimi was more direct in her assessment, staking her “best idea” designation squarely on EDG-7500. Currently in Phase 2 trials, the drug is on track for a critical data readout in the second quarter. Rahimi believes its differentiated mechanism of action sets it apart from existing HCM treatments. Should the drug gain approval, this uniqueness, in her view, will form a durable competitive moat.
However, the bullish case for Edgewise isn’t resting on a single candidate. Just last week, the company released long-term data from a study of sevasemten, its treatment for muscular dystrophy. The results showed that patients with Becker muscular dystrophy experienced stabilization of function, a outcome the company noted is “in marked contrast” to the functional decline typically seen in the disease’s natural history.
This positive data reinforces the company’s research capabilities. While Rahimi did not explicitly cite sevasemten, her confidence in the company’s “multiple other pipeline programs” implicitly includes it. Romero’s optimism was likely bolstered by the data as well.
With two high-potential assets in late-stage development—and two additional cardiovascular programs in the pipeline—Edgewise is building a level of depth that distinguishes it from many peers in the biotech sector.
Rahimi and Romero are not simply echoing each other; they are approaching the same company from complementary angles. Rahimi emphasizes EDG-7500’s differentiated profile and its strategic importance as a top pick. Romero quantifies the opportunity, adjusting her price target to reflect both the renewed focus on EDG-7500 and the encouraging sevasemten data.
In biotech, pipelines are foundational, and clinical data is what ultimately moves markets. Edgewise’s deep focus on cardiovascular and musculoskeletal diseases, combined with positive signals from its two core programs, has successfully captured the attention of Wall Street. This isn’t just a story about two analysts liking a single drug; it’s a validation of the company’s broader research strategy. With the highly anticipated EDG-7500 data on the horizon, the recent analyst activity has undoubtedly raised the stakes for what comes next.
